First-in-Class B7-H3 x MUC1 Bispecific ADC: Redefining Precision in Solid Tumor Therapy

Following a week of major oncology milestones—including strategic platform collaborations with Moonlight Bio, Taisho Pharmaceutical and FDA IND clearance for NEOK Bio’s MUC1-targeting bsADC—Biocytogen continues to validate our platform’s ability to translate discovery assets into clinical reality. Solid tumors present a monumental global challenge, affecting over 10 million patients annually in a therapeutics market projected to exceed $300 billion by 2030. To meet this urgent need, Biocytogen introduces BCG041, a transformative, first-in-class B7-H3 x MUC1 bispecific antibody-drug conjugate (ADC) specifically engineered to enhance tumor targeting and overcome antigen heterogeneity. 

Biocytogen’s Next-Generation Solutions: Why B7-H3 and MUC1?

► B7-H3 (CD276): The Stable Anchor

B7-H3, a member of the B7 immunoregulatory protein family, is practically undetectable in healthy tissues but heavily upregulated across the majority of solid tumors.

The Good:

• B7-H3 in Cancer: Within the TME, B7-H3 does double duty. It acts as an immune checkpoint, helping the tumor hide from the body's defenses, while simultaneously driving tumor aggressiveness, invasion, and metastasis via oncogenic signaling pathways.
• The Prime ADC Target: A major hurdle in oncology is tumor heterogeneity—the reality that cancer cells within a single tumor can mutate and behave differently. B7-H3 is an exceptional target because its expression remains remarkably stable and uniform across different disease states and stages. This makes it an incredibly reliable "anchor" for ADCs, ensuring consistent tumor binding.

The Limit—Monoclonal Limitation: Relying on a single target leaves a dangerous vulnerability. If a fraction of cancer cells downregulates B7-H3, they can survive the treatment and drive an aggressive relapse. Therefore, a secondary anchor is required.

► MUC1: Ideal Partner for Achieving Game-Changing Efficacy

To close the escape route left by B7-H3, a secondary target must be equally prevalent but biologically distinct. Mucin 1 (MUC1) is the perfect candidate. While it acts as a protective glycoprotein in healthy cells, it undergoes a dangerous transformation in cancer, making it an irresistible target due to unique cancerous shifts (Grewal. and Kurzrock. 2025)

The Good:

1. Massive Overexpression: MUC1 expression explodes across high-prevalence solid tumors (including breast, lung, colorectal, and prostate).
2. Tumor-Specific Epitopes: Cancer cells fail to fully glycosylate MUC1, exposing the underlying protein backbone as a unique epitope for therapeutic engagement while minimizing off-target risk to healthy tissues.
3. Loss of Polarity: Unlike healthy epithelial cells where MUC1 is restricted to the apical surface, tumor cells lose this structural polarity. MUC1 is redistributed and spread across the entire 360-degree cell membrane, making it extremely accessible to drugs in the circulation.
4. Critical Oncogenic Driver: MUC1 actively drives tumor proliferation and metastasis, meaning tumors cannot easily mutate or downregulate MUC1 without compromising their own viability.

The Limit— MUC1 “Sink Effect”: Despite decades of promise, MUC1 has remained notoriously difficult to drug. Clinical-stage therapies (e.g. cantuzumab, gatipotuzumab) have historically failed due to the "sink effect"—a process where MUC1 naturally cleaves its extracellular domain, shedding massive amounts of "decoys" into the TME. Traditional antibodies bind to these floating decoys and are neutralized before they can ever reach the cancer cell membrane.

When therapies target a single antigen, the heterogeneous nature of solid tumors allows cancer cells to evade treatment, leading to resistance and relapse. The field urgently needs a solution that can widen the therapeutic window while delivering superior safety and efficacy.

Biocytogen’s BCG041: A Strategic Masterpiece of Bispecific Synergy

BCG041, a first-in-class B7-H3 x MUC1 bispecific ADC, is designed to address the core failures of previous generations through three key mechanisms:

• Dual-Anchor Precision: BCG041 leverages the high B7-H3/MUC1 co-expression across major solid tumors, providing a dual-anchor system that ensures robust tumor engagement even if one target fluctuates—overcoming tumor heterogeneity.
• Bypassing the MUC1 "Sink Effect": Instead of targeting the easily shed outer portions of MUC1, BCG041 targets the membrane-proximal region—the domain that remains firmly attached to the cell. This guarantees the therapy reaches the tumor rather than being wasted by floating decoys in the TME. (See details of our innovation: Discovery of a fully human antibody to the proximal membrane terminus of MUC1 based on a B-cell high-throughput screening technique - PubMed)
• Enhanced Internalization: Engaging two internalizing targets simultaneously increases avidity and triggers much faster internalization—significantly accelerating payload delivery and thus widening the therapeutic window.

► Key Features:

• RenLite^® Fully Human Backbone: Built on our RenLite^® platform, the fully human IgG1κ common-light-chain backbone delivers high affinity, strong developability, and minimized chain mispairing risk—supporting efficient, scalable manufacturing.
• Optimized Linker-Payload System: Features a hydrophilic, protease-cleavable linker with BCPT02 (DAR~8), a novel potent Topo I inhibitor, designed to maximize intracellular payload release and cytotoxic potency while maintaining stability.

► Development Stage & Market Potential:

• IND Readiness: PCC selected; CMC cell line development & NHP dose-range-finding toxicology studies in progress.
• Indications & Market Opportunity: High-prevalence solid tumors with target co-expression—including breast, lung, colorectal, prostate cancers and many others.

► Preclinical Performance:

• Enhanced Cellular Activity: Demonstrates synergistically improved binding, faster internalization, and stronger cytotoxicity compared with parental ADCs and benchmark comparators.
• Robust Antitumor Efficacy: Shows superior tumor growth inhibition in breast cancer models relative to parental ADCs and benchmarks, with observed body weight recovery indicating a potentially improved therapeutic window and superior tolerability compared to aggressive cancer treatment.
• Strong Developability: Favorable PK profiles and good stability.

► Data Highlight:

BCG041 demonstrates more robust in vitro cytotoxicity than monospecific clinical-stage benchmarks in B7-H3/MUC1 dual-expressing breast cancer cells. (Benchmark analogs: Phase II/III B7-H3 targeting ADC DS-7300; Phaes I/II MUC1 targeting ADC gatipotuzumab , both by Daiichi Sankyo)

In the cachectic breast cancer model, a single dose of BCG041 (orange line) demonstrates (A) synergistic tumor growth inhibition compared to parental ADCs and benchmark therapies, alongside (B) body weight recovery, indicating a markedly improved therapeutic window and tolerability—an outcome rarely achieved with aggressive oncology treatments.

► Full data package will be released at the upcoming AACR 2026, stay tuned!

Partnering with Biocytogen for the Future

Biocytogen is actively seeking strategic partnerships for BCG041. This PCC-stage asset is currently available for licensing and co-development, offering a prime opportunity to bring a breakthrough solid tumor therapy to patients. Connect with Biocytogen at the upcoming AACR meeting (Booth # 3225) to review the full dataset and discuss collaborative opportunities!

Frequently Asked Question: B7-H3 x MUC1 Therapy

1. How does BCG041’s dual-targeting approach overcome the failures of previous MUC1 and B7-H3 therapies?

BCG041 leverages high co-expression pattern of B7-H3 (a stable tumor anchor) and MUC1 (a potent oncogenic driver) as a dual-anchor system. This compensates for antigen heterogeneity—ensuring tumor engagement even if one target fluctuates. Critically, it overcomes the historical "sink effect" by targeting the membrane-proximal region of MUC1 rather than its easily shed outer portions, ensuring the payload reaches tumor cells instead of being neutralized by floating decoys.

2. What makes the engineering behind the BCG041 (B7-H3 x MUC1-targeting bsADC) unique?

BCG041 is built on Biocytogen’s proprietary RenLite^® platform. It utilizes a fully human IgG1κ common-light-chain backbone that delivers high binding affinity and strong developability. This advanced engineering minimizes the risk of chain mispairing, which supports efficient and scalable CMC manufacturing for clinical development.

3. How does the BCG041 payload system improve both safety and efficacy?

BCG041 features an optimized, protease-cleavable hydrophilic linker conjugated to BCPT02—a potent Topoisomerase I inhibitor—with a high drug-to-antibody ratio (DAR) of approximately 8. Engaging two targets simultaneously triggers much faster internalization, widening the therapeutic window. Notably, in preclinical cachectic breast cancer models, BCG041 delivered superior antitumor efficacy while promoting unique body weight recovery in diseased mice, indicating a vastly improved tolerability profile compared to aggressive oncology treatments.

4. Which cancer types are the primary targets for BCG041 (B7-H3 x MUC1-targeting bsADC)?

Because B7-H3 and MUC1 are widely co-expressed across a multitude of high-prevalence solid tumors, BCG041 is designed for a massive global patient population. Key targeted indications include breast, lung, colorectal, prostate, esophageal, gastric, head and neck, and metastatic ovarian cancers.